PAPER Loas G, Duru C, Godefroy O, Krystkowiak P

Hedonic deficits in Parkinson's disease: is consummatory anhedonia specific?

Front Neurol. 2014;5:24. Epub 2014 Mar 10 PubMed: 24653714

PAPER Dorszewska J, Prendecki M, Lianeri M, Kozubski W

Molecular Effects of L-dopa Therapy in Parkinson's Disease.

Curr Genomics. 2014 Feb;15(1):11-7. PubMed: 24653659

PAPER Dorszewska J

Genetics of Parkinson's disease and other diseases of the extrapyramidal system.

Curr Genomics. 2014 Feb;15(1):1. PubMed: 24653657

PAPER Morais VA, Haddad D, Craessaerts K, De Bock PJ, Swerts J, Vilain S, Aerts L, Overbergh L, Grünewald A, Seibler P, Klein C, Gevaert K, Verstreken P, De Strooper B

PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling.

Science. 2014 Apr 11;344(6180):203-7. Epub 2014 Mar 20 PubMed: 24652937

PAPER L'episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Serapide MF, Pluchino S, Marchetti B

Wnt/β-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson's disease.

Stem Cells. 2014 Mar 20; PubMed: 24648001

PAPER Kazlauskaite A, Kelly V, Johnson C, Baillie C, Hastie CJ, Peggie M, Macartney T, Woodroof HI, Alessi DR, Pedrioli PG, Muqit MM

Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity.

Open Biol. 2014 Mar 19;4:130213. PubMed: 24647965

PAPER Bloem BR, Munneke M

Revolutionising management of chronic disease: the ParkinsonNet approach.

BMJ. 2014 Mar 19;348:g1838. PubMed: 24647365

PAPER Welter ML, Schüpbach M, Czernecki V, Karachi C, Fernandez-Vidal S, Golmard JL, Serra G, Navarro S, Welaratne A, Hartmann A, Mesnage V, Pineau F, Cornu P, Pidoux B, Worbe Y, Zikos P, Grabli D, Galanaud D, Bonnet AM, Belaid H, Dormont D, Vidailhet M, Mallet L, Houeto JL, Bardinet E, Yelnik J, Agid Y

Optimal target localization for subthalamic stimulation in patients with Parkinson disease.

Neurology. 2014 Apr 15;82(15):1352-61. Epub 2014 Mar 19 PubMed: 24647024

PAPER Cenci MA

Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.

Biochem Soc Trans. 2014 Apr;42(2):600-4. PubMed: 24646284

Lisa Bendixen

University of Western Sydney

Cindy Tucker

private practice
Wilmington

Plinio Hurtado

Royal Adelaide Hospital
Australia

Combination Trial Debate Energizes Keystone Symposium

CONFERENCE COVERAGE 2014-03-21 Conference Coverage Just after the first A4 trial volunteers were screened in San Diego on February 28, study leader Reisa Sperling, Brigham and Women's Hospital, Boston, was already laying out her vision for A5, A6, and even A7 trials at a Keystone

Maya Desai

Navigant

Jerry Nielson

Allergan
Scotch Plains, United States